NewsSTAT
Ranked by formulaVerdict: RoutineMerck and Moderna have 'lot of exploring to do' after initial cancer vaccine success
Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.
Score█████░░░░░5.0
VerdictCompetent work. Briefs at most.
Summary from the source
Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 15% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | ██░░░ 2 | 20% | Limited: single setting, weak baselines, or an observational association presented as causal. |
| Novelty | ██░░░ 2 | 10% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 10% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars); stakes (major disease, prevention or cure).
How the score was computed
Score█████░░░░░5.0
- Merit
- 3.8 / 10
- Adjusted merit
- 3.9 / 10
- Attention
- 28%
- Freshness
- 93%